Literature DB >> 31504331

Debridement, Antibiotics, and Implant Retention Is a Viable Treatment Option for Early Periprosthetic Joint Infection Presenting More Than 4 Weeks After Index Arthroplasty.

Claudia A M Löwik1, Javad Parvizi2, Paul C Jutte1, Wierd P Zijlstra3, Bas A S Knobben4, Chi Xu2, Karan Goswami2, Katherine A Belden5, Ricardo Sousa6, André Carvalho7, Juan Carlos Martínez-Pastor7, Alex Soriano8, Marjan Wouthuyzen-Bakker9.   

Abstract

BACKGROUND: The success of debridement, antibiotics, and implant retention (DAIR) in early periprosthetic joint infection (PJI) largely depends on the presence of a mature biofilm. At what time point DAIR should be disrecommended is unknown. This multicenter study evaluated the outcome of DAIR in relation to the time after index arthroplasty.
METHODS: We retrospectively evaluated PJIs occurring within 90 days after surgery and treated with DAIR. Patients with bacteremia, arthroscopic debridements, and a follow-up <1 year were excluded. Treatment failure was defined as (1) any further surgical procedure related to infection; (2) PJI-related death; or (3) use of long-term suppressive antibiotics.
RESULTS: We included 769 patients. Treatment failure occurred in 294 patients (38%) and was similar between time intervals from index arthroplasty to DAIR: the failure rate for Week 1-2 was 42% (95/226), the rate for Week 3-4 was 38% (143/378), the rate for Week 5-6 was 29% (29/100), and the rate for Week 7-12 was 42% (27/65). An exchange of modular components was performed to a lesser extent in the early post-surgical course compared with the late course (41% vs 63%, respectively; P < .001). The causative microorganisms, comorbidities, and durations of symptoms were comparable between time intervals.
CONCLUSIONS: DAIR is a viable option in patients with early PJI presenting more than 4 weeks after index surgery, as long as DAIR is performed within at least 1 week after the onset of symptoms and modular components can be exchanged.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  DAIR; early prosthetic joint infection; failure; joint arthroplasty; time interval

Year:  2020        PMID: 31504331     DOI: 10.1093/cid/ciz867

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

1.  Biofilm properties in relation to treatment outcome in patients with first-time periprosthetic hip or knee joint infection.

Authors:  Karin Svensson Malchau; Jonatan Tillander; Magdalena Zaborowska; Maria Hoffman; Iñigo Lasa; Peter Thomsen; Henrik Malchau; Ola Rolfson; Margarita Trobos
Journal:  J Orthop Translat       Date:  2021-08-19       Impact factor: 5.191

2.  One-year infection control rates of a DAIR (debridement, antibiotics and implant retention) procedure after primary and prosthetic-joint-infection-related revision arthroplasty - a retrospective cohort study.

Authors:  F Ruben H A Nurmohamed; Bruce van Dijk; Ewout S Veltman; Marrit Hoekstra; Rob J Rentenaar; Harrie H Weinans; H Charles Vogely; Bart C H van der Wal
Journal:  J Bone Jt Infect       Date:  2021-01-27

3.  Exchange of Modular Components Improves Success of Debridement, Antibiotics, and Implant Retention: An Observational Study of 575 Patients with Infection After Primary Total Hip Arthroplasty.

Authors:  Karin Svensson; Ola Rolfson; Emma Nauclér; Stergios Lazarinis; Olof Sköldenberg; Jörg Schilcher; Per-Erik Johanson; Maziar Mohaddes; Johan Kärrholm
Journal:  JB JS Open Access       Date:  2020-12-15

4.  Do Prosthetic Joint Infections Worsen the Functional Ambulatory Outcome of Patients with Joint Replacements? A Retrospective Matched Cohort Study.

Authors:  Isabel Mur; Marcos Jordán; Alba Rivera; Virginia Pomar; José Carlos González; Joaquín López-Contreras; Xavier Crusi; Ferran Navarro; Mercè Gurguí; Natividad Benito
Journal:  Antibiotics (Basel)       Date:  2020-12-05

5.  A protocol for periprosthetic joint infections from the Northern Infection Network for Joint Arthroplasty (NINJA) in the Netherlands.

Authors:  W P Zijlstra; J J W Ploegmakers; G A Kampinga; M L Toren-Wielema; H B Ettema; B A S Knobben; P C Jutte; M Wouthuyzen-Bakker
Journal:  Arthroplasty       Date:  2022-04-11

6.  Puerarin@Chitosan composite for infected bone repair through mimicking the bio-functions of antimicrobial peptides.

Authors:  Liping Ouyang; Baohui Chen; Xingdan Liu; Donghui Wang; Yang Li; Yun Liao; Kelvin W K Yeung; Xuanyong Liu
Journal:  Bioact Mater       Date:  2022-09-20

7.  Effectiveness of Different Antimicrobial Strategies for Staphylococcal Prosthetic Joint Infection: Results From a Large Prospective Registry-Based Cohort Study.

Authors:  Henk Scheper; Robert J P van der Wal; Rachid Mahdad; Stefan Keizer; Nathalie M Delfos; Joris C T van der Lugt; Karin Ellen Veldkamp; Peter A Nolte; Masja Leendertse; Luc B S Gelinck; Femke P N Mollema; Emile F Schippers; Hanke G Wattel-Louis; Leo G Visser; Rob G H H Nelissen; Mark G J de Boer
Journal:  Open Forum Infect Dis       Date:  2022-09-13       Impact factor: 4.423

Review 8.  Outcome of Debridement, Antibiotics, and Implant Retention for Staphylococcal Hip and Knee Prosthetic Joint Infections, Focused on Rifampicin Use: A Systematic Review and Meta-Analysis.

Authors:  H Scheper; L M Gerritsen; B G Pijls; S A Van Asten; L G Visser; M G J De Boer
Journal:  Open Forum Infect Dis       Date:  2021-07-01       Impact factor: 3.835

9.  The role of fibrinogen in predicting reinfection after DAIR for periprosthetic joint infections.

Authors:  Dacheng Zhao; Jinwen He; Xingwen Wang; Xiaobing Zhao; Yayi Xia; Bin Geng
Journal:  BMC Musculoskelet Disord       Date:  2021-05-24       Impact factor: 2.362

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.